Patient population in diabetes and obesity increases continuously. In particular, obesity patient is expected to increase more than 50% within next 10 years. As a result, the global market size for diabetes and obesity in 2011 reached 30 billion dollars, and is still growing. Correlation between the onset of obesity and diabetes are known to be high.

KM001 project is to develop DGAT1 (Diacylglycerol acyltransferase 1) inhibitor which reduce TG synthesis. The mode of action for DGAT1 inhibitor is different with current anti-obesity therapeutics, and the research shows Kainos compound has efficacy for reducing TG synthesis and body weight in DIO(Diet Induced Obesity) mouse model study. So the goal of this project is to develop first-in-class drug. Lead optimization is completed and Kainos is seeking collaboration partner for further development like preclinical study.